Pacira Pharmaceuticals (NASDAQ:PCRX)

CAPS Rating: 1 out of 5

Results 1 - 7 of 7

Recs

0
Member Avatar Ssteffey (< 20) Submitted: 3/28/2014 2:28:54 PM : Outperform Start Price: $62.38 PCRX Score: +34.48

exparel is a game changing product

Recs

0
Member Avatar KKR (< 20) Submitted: 1/28/2014 3:39:38 PM : Outperform Start Price: $64.26 PCRX Score: +26.71

good product with expanding indications

Recs

0
Member Avatar jjschult (< 20) Submitted: 10/11/2012 3:07:15 PM : Outperform Start Price: $17.68 PCRX Score: +359.66

Novel delivery mechanism for generic bipuvicaine that enables 72-hour post-surgery pain relief with a single shot, minimizing the need for opioids. Zero competition and huge target market. Potential to double in 18-24 months.

Recs

0
Member Avatar BKoretz (< 20) Submitted: 10/4/2012 9:55:27 AM : Outperform Start Price: $18.80 PCRX Score: +331.91

Their single product, an injectable, long lasting pain reliever, is going to revolutionize post surgical patient care.

Recs

0
Member Avatar DSmod (37.17) Submitted: 7/3/2012 12:30:39 PM : Underperform Start Price: $16.01 PCRX Score: -404.77

Driven up too high on excitement over one drug--which itself will not bring these guys into profitability.

Recs

0
Member Avatar jsrichards (96.56) Submitted: 6/11/2012 2:55:26 PM : Outperform Start Price: $13.06 PCRX Score: +523.71

This drug will enable providers to send their patients home with minimal narcotics, providing days of minimal post-operative pain, without the untoward complications.

Recs

0
Member Avatar PharmaD (91.35) Submitted: 10/26/2011 11:17:21 PM : Outperform Start Price: $11.39 PCRX Score: +616.78

Nda approval for exparel

Results 1 - 7 of 7

Featured Broker Partners


Advertisement